These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 4212370

  • 1. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides.
    Castensson S, Sievertsson H, Lindeke B, Sum CY.
    FEBS Lett; 1974 Aug 15; 44(1):101-5. PubMed ID: 4212370
    [No Abstract] [Full Text] [Related]

  • 2. Hypothalamic releasing factors and Parkinson disease.
    Chase TN, Woods AC, Lipton MA, Morris CE.
    Arch Neurol; 1974 Jul 15; 31(1):55-6. PubMed ID: 4209275
    [No Abstract] [Full Text] [Related]

  • 3. Inactivation of melanocyte-stimulating hormone release-inhibiting factor by a manganese-stimulated bovine brain aminopeptidase.
    Simmons WH, Brecher AS.
    J Biol Chem; 1973 Aug 25; 248(16):5780-4. PubMed ID: 4353274
    [No Abstract] [Full Text] [Related]

  • 4. Structure-activity studies of MSH-release-inhibiting hormone.
    Celis ME, Hase S, Walter R.
    FEBS Lett; 1972 Nov 01; 27(2):327-30. PubMed ID: 4352026
    [No Abstract] [Full Text] [Related]

  • 5. 13C nuclear magnetic resonance studies of the conformation of the X-pro bond in the oligopeptide hormones, thyrotropin-releasing hormone, luteinizing hormone-releasing factor, angiotensin and melanocyte-stimulating hormone release-inhibiting factor.
    Deslauriers R, Walter R, Smith IC.
    Biochem Biophys Res Commun; 1973 Jul 02; 53(1):244-50. PubMed ID: 4354931
    [No Abstract] [Full Text] [Related]

  • 6. Carbon-13 NMR studies of peptide hormones and their components.
    Smith IC, Deslauriers R, Saitô H, Walter R, Garrigou-Lagrange C, McGregor H, Sarantakis D.
    Ann N Y Acad Sci; 1973 Dec 31; 222():597-627. PubMed ID: 4361873
    [No Abstract] [Full Text] [Related]

  • 7. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice.
    Huidobro-Toro JP, De Carolis AS, Longo VG.
    Pharmacol Biochem Behav; 1974 Dec 31; 2(1):105-9. PubMed ID: 4364044
    [No Abstract] [Full Text] [Related]

  • 8. Isolation and structure of hypothalamic MSH release-inhibition hormone.
    Nair RM, Kastin AJ, Schally AV.
    Biochem Biophys Res Commun; 1971 Jun 18; 43(6):1376-81. PubMed ID: 4398196
    [No Abstract] [Full Text] [Related]

  • 9. General activity in intact and hypophysectomized rats after administration of melanocyte-stimulating hormone (MSH), melatonin, and PRO-LEU-GLY-NH 2 .
    Kastin AJ, Miller MC, Ferrell L, Schally AV.
    Physiol Behav; 1973 Feb 18; 10(2):399-401. PubMed ID: 4575310
    [No Abstract] [Full Text] [Related]

  • 10. Behavioral effects of thyrotropin releasing hormone in animals and man: a generic hypothesis.
    Prange AJ, Wilson IC.
    Psychopharmacol Bull; 1975 Jan 18; 11(1):22-4. PubMed ID: 804704
    [No Abstract] [Full Text] [Related]

  • 11. Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
    Björkman S, Castensson S, Lindeke B, Sievertsson H.
    Acta Pharm Suec; 1976 Jan 18; 13(4):289-98. PubMed ID: 11638
    [No Abstract] [Full Text] [Related]

  • 12. Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study.
    Ehrensing RH, Kastin AJ.
    Arch Gen Psychiatry; 1974 Jan 18; 30(1):63-5. PubMed ID: 4587068
    [No Abstract] [Full Text] [Related]

  • 13. Site of inactivation of melanocyte-stimulating hormone-release-inhibiting hormone by human plasma.
    Nair RM, Redding TW, Kastin AJ, Schally AV.
    Biochem Pharmacol; 1973 Aug 01; 22(15):1915-9. PubMed ID: 4578947
    [No Abstract] [Full Text] [Related]

  • 14. Chemistry of releasing hormones.
    Sandow J.
    J Endocrinol; 1973 Aug 01; 58(2):32-3. PubMed ID: 4199267
    [No Abstract] [Full Text] [Related]

  • 15. Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom.
    Fischer PA, Schneider E, Jacobi P, Maxion H.
    Eur Neurol; 1974 Aug 01; 12(5-6):360-8. PubMed ID: 4614981
    [No Abstract] [Full Text] [Related]

  • 16. Activity of a new synthetic tetrapeptide in hypothalamic luteinizing and follicle stimulating releasing hormone assay systems.
    Bowers CY, Chang JK, Sievertsson H, Bogentoft C, Currie BL, Folkers K.
    Biochem Biophys Res Commun; 1971 Jul 16; 44(2):414-21. PubMed ID: 5003612
    [No Abstract] [Full Text] [Related]

  • 17. Biosynthesis of hypothalamic hypophysiotropic factors.
    Reichlin S, Mitnick M.
    Front Neuroendocrinol; 1973 Jul 16; 0(0):61-88. PubMed ID: 4137560
    [No Abstract] [Full Text] [Related]

  • 18. Hypothalamic regulatory hormones.
    Schally AV, Coy DH, Meyers CA.
    Annu Rev Biochem; 1978 Jul 16; 47():89-128. PubMed ID: 28075
    [No Abstract] [Full Text] [Related]

  • 19. Thyrotropin releasing hormone (TRH): restoration of oxotremorine tremor in mice. Comparison with quipazine, a serotoninergic and dopaminergic stimulant.
    Kruse H.
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Jul 16; 294(1):39-45. PubMed ID: 12478
    [Abstract] [Full Text] [Related]

  • 20. Melanocyte-stimulating hormone and parkinsonism: the role of hypothalamic releasing factors.
    Sandler M, Goodwin BL, Leask BG, Ruthven CR.
    Lancet; 1973 Mar 17; 1(7803):612. PubMed ID: 4120682
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.